37893-08-6Relevant articles and documents
SYNTHESIS AND STUDY OF HETEROAROMATIC LIGANDS CONTAINING A PYRIMIDINE RING
Ivashchenko, A. V.,Garicheva, O. N.,Shmelev, L. V.,Ryabokobylko, Yu. S.,Adamova, G. M.
, p. 1271 - 1275 (1980)
5-Hexyl-3-amino-1(2)H-1,2,4-triazoles and 2-(3,5-dipropyl-4-ethyl-1H-pyrazol-1-yl)-6-methyl-4-(5-methyl-1H-pyrazol-1-yl)aminopyrimidine were synthesized by the reaction of 4-chloropyrimidines with 3-amino-5-hexyl-1H-1,2,4-triazole and 3-amino-5-methyl-1H-pyrazole.Their IR, UV, and PMR spectra were investigated.New methods for the preparation of the intermediates, viz., 2-hydrazino-4(3H)-pyrimidinones and 2-(1H-pyrazol-1-yl)-4(3H)-pyrimidinones, that make it possible to obtain these compounds in higher yields are described.
Synthesis, antibacterial, antioxidant, and molecular docking studies of 6-methylpyrimidin-4(3H)-one and oxo-1,2,4-triazolo[4,3-a]pyrimidine derivatives
El Ashry, El Sayed H.,Awad, Laila F.,Badawy, Mohamed E.I.,Rabea, Entsar I.,Ibrahim, Nihal A.,Al Moaty, Mohamed N. Abd
, (2021/10/04)
A series of 6-methylpyrimidin-4(3H)-one and oxo-1,2,4-triazolo[4,3-a]pyrimidine derivatives (1-18) was designed to meet the urgent need for novel antibacterial and antioxidant agents. The in vitro antibacterial activity revealed that most of the compounds exhibited a good inhibitory effect on Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria with MIC values in the range of 55–200 μg/mL for E. coli and 125–700 μg/mL for S. aureus. (E)-2-(2-(4-methoxybenzylidene)hydrazinyl)-6-methylpyrimidin-4(3H)-one (8) was the most active compound (MIC = 55 and 125 μg/mL against E. coli and S. aureus, respectively). All compounds exhibited antioxidant activity ranged from weak to moderate and high. The obtained findings revealed that compounds 3, 5, 6, 9, 16, and 18 have superiority among all compounds, demonstrating the highest capacity to deplete DPPH (1,1-diphenyl-2-picrylhydrazyl), compared to α-tocopherol, as a standard antioxidant agent. Surprisingly, compound 3 (2-hydrazinyl-6-methylpyrimidin-4(3H)-one) showed significantly higher antioxidant activity (EC50 = 2.12 μg/mL) than α-tocopherol (EC50 = 9.16 μg/mL). Molecular docking, drug-likeness data, physicochemical properties, and ADMET parameters of the compounds were in silico computed. The derivatives presented good properties for Lipinski's parameters, poor solubility in the aqueous medium (Log S of -1.27 to -5.45), and PSA ≤140, indicating good permeability in biological membranes and gastrointestinal absorption. Molecular docking to the active sites of penicillin-binding protein and NADPH oxidase revealed that most compounds displayed minimal binding energy and have a good affinity toward the active pocket.
NOVEL ANTIPARASITIC COMPOUNDS AND METHODS
-
Page/Page column 92-93, (2021/04/23)
Novel compounds for treating or inhibiting leishmaniasis and other parasitic protozoan diseases are disclosed herein. The compounds bind to Leishmania tubulin, induce parasite microtubule polymerization, stall Leishmania cell division, and have broad antiparasitic activity.
NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE
-
Paragraph 0154, (2019/02/05)
The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
